Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keyzilen in Acute Peripheral Tinnitus
NCT02040194Phase 3Completed
- Sponsor
- Altamira Therapeutics
- Start
- Jan 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esketamine in tinnitus (2 arms), sponsored by Altamira Therapeutics. Primary endpoints: Tinnitus Functional Index at Day 84 and Tinnitus Loudness Numerical Rating Scale at Day 84. Started Jan 2014; status: completed.
02
Drugs
esketamine
03
Conditions
tinnitus
Beyond the preview
Go deeper on NCT02040194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02040194.